Cannabix Technologies Adds Dr. Randall Purves as Scientific Advisor
May 13 2019 - 8:35AM
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the
“Company”) is pleased to announce that Dr. Randy Purves has been
appointed as a Scientific Advisor to Cannabix Technologies Inc. Dr.
Purves is one of the world’s foremost experts in the development of
FAIMS (high-field asymmetric waveform ion mobility spectrometry)
instrumentation and applications. Dr. Purves is a pioneer in
developing FAIMS technology and in 2001 he co-founded Ionalytics,
an instrument company specializing in FAIMS devices for use with
mass spectrometry. Ionalytics was acquired by Thermo Electron (now
Thermo Fisher Scientific) in 2005 and Dr. Purves was part of the
Thermo team involved with the commercial release of an integrated
FAIMS product for use with a TSQ Quantum mass spectrometer in 2006.
Dr. Randy Purves obtained his Ph.D. in Analytical Chemistry from
the University of Alberta. Dr. Purves has over 25 years of
experience working with mass spectrometry, which includes working
in drug metabolism at Merck Frosst. Dr. Purves is an expert in
the development and application of FAIMS, having co-authored 45
refereed publications in FAIMS and differential mobility
spectrometry (DMS) in general. Dr. Purves is an adjunct professor
in the College of Pharmacy and Nutrition at the University of
Saskatchewan and continues to collaborate with Thermo Fisher
Scientific on further enhancing FAIMS technology for mass
spectrometry based applications. A primary interest of Dr.
Purves is to use his expertise in FAIMS and small molecule analysis
to improve quantification methods of analytes in challenging
matrices.
Dr. Raj Attariwala, Cannabix’s Chief Scientific Officer, states,
“Dr. Purves has deep, unparalleled experience with FAIMS technology
that will be a tremendous benefit to our scientific team and
technology development.”
The Company has granted Dr. Purves 150,000 stock options
exercisable at $1.50 for a period of 2 years.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer
development for law enforcement and the workplace. Cannabix has
established breath testing technologies in the pursuit of bringing
durable, portable hand-held tools to market to enhance detection of
marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects previous usage from days or
even weeks earlier. The devices will also be useful for other
practical applications such as testing employees in the workplace
where impairment by THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEOCannabix Technologies Inc.
For further information, contact the Company at
info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that
involves various risks and uncertainties regarding future events.
Such forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Sep 2023 to Sep 2024